Could a vaccine stop cancer before it starts? lynch syndrome trial launches
NCT ID NCT07163403
First seen Oct 31, 2025 · Last updated Apr 29, 2026 · Updated 21 times
Summary
This study tests a new vaccine made from a person's own immune cells, designed to teach the body to recognize and attack cells that could become cancer. It is for adults with Lynch syndrome, a genetic condition that raises cancer risk. The main goals are to check safety and see if the vaccine sparks an immune response. Twenty participants will receive the vaccine and be monitored for one year.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYNCH SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Laura Burunat
RECRUITINGBarcelona, Barcelona, 08036, Spain
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.